Key facts
- This page summarizes Ira Duarte's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Aug 2026, 09:50.
Ira Duarte - 30 Jul 2026 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)
- Reporting relationship
- EVP, Chief Financial Officer
- Issuer ticker
- HRTX
- Reported as of
- 30 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Aug 2026, 09:50:25 UTC
- Prior SEC filing
- 20 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/Kathryn Lester Attorney-in-fact for Ira Duarte
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ira Duarte filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 03 Aug 2026.
Change
- Previous filing in this sequence was filed on 20 Jul 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001488864
Primary reporting owner
Duarte Ira
- Relationship
- EVP, Chief Financial Officer
- Address
- 25 FENTON MAIN STREET, SUITE 300, CARY
- Signature
- /s/Kathryn Lester Attorney-in-fact for Ira Duarte
- Signature date
- 03 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HRTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +13,535
- Change %
- +5.1%
- Price
- Shares after
- 277,381
- Date
- 30 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
HRTX
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -3,850
- Change %
- -1.4%
- Price
- $0.5000*
- Shares after
- 273,531
- Date
- 30 Jul 2026
- Ownership
- Direct
HRTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +11,694
- Change %
- +4.3%
- Price
- Shares after
- 285,225
- Date
- 31 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
HRTX
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -3,326
- Change %
- -1.2%
- Price
- $0.5000*
- Shares after
- 281,899
- Date
- 31 Jul 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -13,535
- Change %
- -6.7%
- Price
- $0.000000*
- Shares after
- 189,492
- Date
- 30 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,535
- Exercise price
- $0.000000
- Footnotes
- F2
HRTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -11,694
- Change %
- -9.1%
- Price
- $0.000000*
- Shares after
- 116,944
- Date
- 31 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,694
- Exercise price
- $0.000000
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F2
On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.
Footnote F3
The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).